PHX 1766

Drug Profile

PHX 1766

Alternative Names: PHX1766

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Phenomix Corporation
  • Class Antivirals; Small molecules
  • Mechanism of Action Hepatitis C virus NS3 protein inhibitors; Hepatitis C virus NS4 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Hepatitis C

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Hepatitis-C in Netherlands (PO)
  • 03 Nov 2009 Efficacy and adverse events data from a phase I trial in Hepatitis C presented at the 60th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2009)
  • 29 Oct 2008 Phase-I clinical trials in Hepatitis C in Netherlands (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top